Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBITDA (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed EBITDA for 6 consecutive years, with -$42.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 546.32% year-over-year to -$42.7 million, compared with a TTM value of -$64.3 million through Dec 2025, down 1259.99%, and an annual FY2025 reading of -$64.3 million, down 1259.7% over the prior year.
  • EBITDA was -$42.7 million for Q4 2025 at Cytek Biosciences, down from -$4.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $9.6 million in Q4 2024 and bottomed at -$42.7 million in Q4 2025.
  • Average EBITDA over 5 years is -$3.8 million, with a median of -$1.6 million recorded in 2022.
  • Peak annual rise in EBITDA hit 6813.1% in 2023, while the deepest fall reached 823.04% in 2023.
  • Year by year, EBITDA stood at $1.3 million in 2021, then tumbled by 93.62% to $84000.0 in 2022, then skyrocketed by 6813.1% to $5.8 million in 2023, then soared by 64.58% to $9.6 million in 2024, then crashed by 546.32% to -$42.7 million in 2025.
  • Business Quant data shows EBITDA for CTKB at -$42.7 million in Q4 2025, -$4.6 million in Q3 2025, and -$5.0 million in Q2 2025.